Profile data is unavailable for this security.
About the company
CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.
- Revenue in HKD (TTM)505.23m
- Net income in HKD-157.49m
- Incorporated2015
- Employees164.00
- LocationCStone Pharmaceuticals1000 Zhangheng Road Bldg 25Pudong New DistrictSUZHOU 200072ChinaCHN
- Phone+86 51 287186550
- Websitehttps://www.cstonepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunotech Biopharm Ltd | 0.00 | -342.21m | 1.51bn | 201.00 | -- | 16.86 | -- | -- | -0.665 | -0.665 | 0.00 | 0.1744 | 0.00 | -- | -- | 0.00 | -35.21 | -37.42 | -55.75 | -45.48 | -- | -- | -- | -- | 0.3638 | -2.46 | 0.6119 | -- | -- | -- | -5.25 | -- | -8.46 | -- |
Hua Medicine | 120.56m | -291.47m | 1.53bn | 172.00 | -- | -- | -- | 12.70 | -0.2973 | -0.2973 | 0.123 | -0.0374 | 0.0779 | 1.51 | 3.31 | 681,148.90 | -18.84 | -25.61 | -23.63 | -28.81 | 37.72 | -- | -241.76 | -1,654.70 | 4.64 | -- | 1.14 | -- | 335.31 | -- | -3.80 | -- | 14.07 | -- |
TOT Biopharm International Co Ltd | 1.08bn | 9.92m | 1.57bn | 572.00 | 148.41 | 1.96 | 22.33 | 1.46 | 0.0137 | 0.0137 | 1.49 | 1.04 | 0.6899 | 2.44 | 6.40 | 1,954,594.00 | 0.6356 | -20.01 | 0.8392 | -25.21 | 72.02 | 74.74 | 0.9212 | -68.53 | 1.63 | 2.98 | 0.3465 | -- | 76.54 | 81.88 | 24.36 | -- | 21.04 | -- |
Mabpharm Ltd | 167.80m | -229.00m | 1.61bn | 297.00 | -- | 12.62 | -- | 9.59 | -0.0555 | -0.0555 | 0.0407 | 0.0309 | 0.164 | 0.1937 | 3.26 | 483,569.00 | -22.38 | -21.42 | -31.11 | -27.49 | 86.91 | -- | -136.47 | -486.40 | 0.6836 | -22.44 | 0.679 | -- | 55.87 | -- | 0.694 | -- | -26.85 | -- |
Jacobio Pharmaceuticals Group Co Ltd | 25.66m | -400.50m | 1.86bn | 298.00 | -- | 1.86 | -- | 72.61 | -0.5159 | -0.5159 | 0.0331 | 1.27 | 0.016 | -- | 2.41 | 85,243.36 | -24.89 | -45.76 | -28.66 | -49.30 | 3.45 | -- | -1,560.88 | -372.22 | -- | -- | 0.1794 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
Frontage Holdings Corp | 2.02bn | 47.37m | 2.18bn | 1.66k | 46.70 | 0.8334 | 6.46 | 1.08 | 0.0229 | 0.0229 | 0.9859 | 1.28 | 0.4701 | 56.23 | 4.58 | 1,147,817.00 | 1.06 | 4.46 | 1.30 | 5.28 | 28.56 | 34.00 | 2.26 | 9.92 | 1.25 | 2.37 | 0.311 | 0.00 | 3.79 | 25.61 | -58.00 | -0.7826 | 40.43 | -- |
Laekna Inc | 0.00 | -327.06m | 2.55bn | 92.00 | -- | 3.41 | -- | -- | -0.9178 | -0.9178 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
ImmuneOnco Biopharmaceuticls Shanghi Inc | 417.22k | -414.33m | 2.69bn | 150.00 | -- | 4.05 | -- | 6,447.96 | -1.15 | -1.15 | 0.0012 | 1.78 | -- | -- | -- | 2,877.35 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
Abbisko Cayman Ltd | 550.32m | -17.93m | 2.78bn | 275.00 | -- | 1.21 | 759.73 | 5.05 | -0.0304 | -0.0304 | 0.8473 | 3.37 | 0.2159 | -- | 65.75 | 2,133,021.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
CStone Pharmaceuticals | 505.23m | -157.49m | 2.80bn | 164.00 | -- | 5.41 | -- | 5.54 | -0.1236 | -0.1236 | 0.3963 | 0.403 | 0.2861 | 1.33 | 2.50 | 2,196,668.00 | -8.92 | -54.76 | -16.99 | -81.68 | 70.73 | -- | -31.17 | -301.62 | 1.45 | -- | 0.4171 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
CARsgen Therapeutics Holdings Ltd | 7.02m | -769.01m | 2.80bn | 477.00 | -- | 1.70 | -- | 399.15 | -1.38 | -1.38 | 0.0126 | 2.88 | 0.0027 | -- | 0.302 | 13,597.51 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
Biocytogen Pharmaceuticals Beijng Co Ltd | 885.98m | -269.83m | 3.91bn | 1.04k | -- | 4.78 | -- | 4.41 | -0.6775 | -0.6775 | 2.22 | 2.05 | 0.3109 | 23.64 | 5.36 | 831,122.00 | -9.47 | -- | -12.44 | -- | 71.97 | -- | -30.46 | -- | 1.33 | -4.18 | 0.436 | -- | 34.28 | -- | 36.38 | -- | -- | -- |
Data as of Oct 09 2024. Currency figures normalised to CStone Pharmaceuticals's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 20.59m | 1.60% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 17.63m | 1.37% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 8.70m | 0.68% |
Templeton Asset Management Ltd.as of 28 Jun 2024 | 4.85m | 0.38% |
Dimensional Fund Advisors LPas of 30 Apr 2024 | 439.50k | 0.03% |
Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 244.50k | 0.02% |
Ping An Fund Management Co., Ltd.as of 31 Dec 2023 | 147.50k | 0.01% |
SSgA Funds Management, Inc.as of 03 Jul 2024 | 137.50k | 0.01% |
Vanguard Global Advisers LLCas of 30 Jun 2024 | 59.00k | 0.01% |
DFA Australia Ltd.as of 30 Jun 2024 | 2.25k | 0.00% |
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.